| Effects of telmisartan on fat distribution in individuals with the metabolic syndrome. | |
MedLine Citation:
|
PMID: 17351377 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Visceral fat obesity plays an essential role in the clustering of atherosclerotic multiple risk factors in the metabolic syndrome. Telmisartan, an angiotensin II type 1 receptor blocker, has partial agonistic properties for peroxisome proliferator-activated receptor gamma, which is a key regulator of adipocyte differentiation and function. METHODS: This study aimed to clarify the impact of telmisartan on fat distribution and insulin sensitivity in the metabolic syndrome. In this open-label, prospective, randomized study, patients with the metabolic syndrome (waist circumference: men >or= 85 cm, women >or= 90 cm) were treated either with amlodipine (n = 26) or with telmisartan (n = 27) for 24 weeks, and fat distribution and insulin sensitivity were determined. RESULTS: Systolic and diastolic blood pressure were decreased in both groups to a comparable level. However, insulin and glucose levels during an oral 75 g glucose loading were decreased only in the telmisartan group. The visceral fat area, determined by abdominal computed tomography scan, was reduced in the telmisartan group after 24 weeks' treatment, but the subcutaneous fat area did not change in either group. CONCLUSION: The results imply that telmisartan could treat both the hemodynamic and metabolic aberrations seen in patients with the metabolic syndrome, improving insulin resistance and glucose intolerance at least partly through visceral fat remodeling. |
Authors:
|
Michio Shimabukuro; Hideaki Tanaka; Takeshi Shimabukuro |
Related Documents
:
|
20219977 - The positive effects of growth hormone-releasing peptide-6 on weight gain and fat mass ... 2647557 - Effect of d-fenfluramine on basal glucose turnover and fat-feeding-induced insulin resi... 17381487 - Interleukin-6, tumour necrosis factor-alpha and insulin relationships to body compositi... 25271207 - Exploring the potential of the sglt2 inhibitor dapagliflozin in type 1 diabetes: a rand... 19911877 - Challenges and advances in nanoparticle-based oral insulin delivery. 19420817 - Familial graves' disease associated with type 1 diabetes. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of hypertension Volume: 25 ISSN: 0263-6352 ISO Abbreviation: J. Hypertens. Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-03-12 Completed Date: 2007-08-07 Revised Date: 2014-01-09 |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: England |
Other Details:
|
Languages: eng Pagination: 841-8 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adipose Tissue, White
/
drug effects* Adult Aged Amlodipine / therapeutic use Analysis of Variance Angiotensin II Type 1 Receptor Blockers / therapeutic use* Aorta / drug effects, physiopathology Benzimidazoles / therapeutic use* Benzoates / therapeutic use* Biological Markers / blood Blood Glucose / drug effects, metabolism Blood Pressure / drug effects Body Fat Distribution Calcium Channel Blockers / therapeutic use Female Glucose Tolerance Test Humans Hypertension / blood, drug therapy, physiopathology Insulin / blood Insulin Resistance Intra-Abdominal Fat / drug effects Male Metabolic Syndrome X / blood, drug therapy*, physiopathology Middle Aged Prospective Studies Research Design Tomography, X-Ray Computed Treatment Outcome Vascular Resistance / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Benzoates; 0/Biological Markers; 0/Blood Glucose; 0/Calcium Channel Blockers; 0/Insulin; 1J444QC288/Amlodipine; U5SYW473RQ/telmisartan |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic s...
Next Document: Babies, pre-eclamptic mothers and grandparents: a three-generation phenotyping study.